[리포트분석]Chong Kun Dang, a corona treatment drug,’Napa Beltan’, a game changer rapidly rises

[이데일리 김지완 기자]It was predicted that Chong Kun Dang’s’Napa Beltan’, which had a license for the domestic 2nd corona treatment, would become the game chamber site.

Turkey Introduces Corona 19 Vaccination Registration System[사진=터키문화관광부]

This is because Napabeltan (ingredient name Napamostat) is 600 times effective in remdesivir, which was confirmed in the laboratory, and has also been proven in clinical practice. Here, it showed higher stability than the existing treatment and emerged as a dark horse. In light of the fact that Napa Beltan was treated as one of several treatments until recently,’One of them’, this is a rapid rise in status.

According to the pharmaceutical bio industry on the 16th, Napa Beltan is expected to receive conditional approval for the treatment of Corona 19 from the Ministry of Food and Drug Safety as early as April. On the 8th, Chong Kun Dang applied for a conditional permission for the treatment of Corona 19 from the Ministry of Food and Drug Safety based on the results of phase 2 clinical trials of Napa Beltan.

Announced in January that the results of the phase 2 clinical trial of Napa Beltan were successful. The improvement rate of severely ill patients taking napabeltan was 94.4%, but the improvement rate in the control group was 61.1%. Moreover, there were no deaths among patients taking Napabeltan, but four deaths were reported in existing treatments.

The Institut Pasteur Korea has proven that Napamostat has 600 times more therapeutic effect than remdesivir in preclinical trials. Here, as various corona mutations appear simultaneously around the world, Napa Beltan is attracting more attention.

An official of Chong Kun Dang explained, “Napabeltan is expected to be effective in the COVID-19 mutation,” and explained, “The treatment is done in a way that Napamostat inhibits the spike protein activating enzyme.”

In other words, Napa Beltan’s treatment mechanism neutralizes the spike protein, which plays a major role in corona 19 virus cell infection, so it is highly likely to be applied to both mutants and coronaviruses. However, clinical trials of Napabeltan for mutation have not yet been carried out.

Coronavirus mutations include the UK mutation (B117), which has a stronger transmission power than the existing virus, the California mutation known to be resistant to antibodies (B1429), and the South African mutation (E484K), which has the ability to avoid antibodies. In addition, new mutant viruses such as the Brazilian mutant (P1) and the second British mutant (B1525) are constantly appearing.

Moreover, as it is known that many of the corona19 deaths have developed pulmonary embolism due to blood clotting, an analysis that Napabeltan is more suitable as a treatment for patients with severe gastric disorders has appeared. Napabeltan has been used as a blood anticoagulant to treat acute pancreatitis.

Napabeltan. [사진=종근당]

As the clinical results and treatment mechanisms of Napa Beltan became known, the market evaluation was also reversed.

In a report on the 15th, Oh Byung-yong, a researcher at Hanyang Securities, said, “There are overflowing candidates for the treatment of Corona 19, but the most anticipated substance is Napamostat.” Reach. Expectations will increase.” In fact, they saw Napabeltan as a substitute for remdesivir.

An official from the pharmaceutical industry mentioned the WHO’s announcement last year that remdesivir has little effect in the treatment of severely ill patients. It is natural that) is attracting attention,” he raised his voice.

Just a month ago, the financial investment industry called Napa Beltan’one of the many treatment options’. It is different from the devaluation such as’it is necessary to lower the eye level on sales expectations and sustainability’.

Chong Kun Dang is busy working for Napa Beltan’s global clinical trial and approval of overseas treatments.

An official from Chong Kun Dang said, “If Napa Beltan is approved by the Ministry of Food and Drug Safety, we plan to conduct global clinical trials.” As in the case of Celltrion Rekirona, I think it can be done easily if there is a fact that it has been approved by the Ministry of Food and Drug Safety.”

Meanwhile, Data Bridge Market Research, a global market research firm, predicted that remdesivir will grow at an annual average of 27.47% on the 10th to form a market worth 99.3 billion dollars (11.2 trillion won) in 2028. Remdesivir achieved sales of 2.8 billion dollars (about 3 trillion won) last year.